Evaluation of anti-psychotic effect of nimodipine using methylphenidate as a model to induce psychosis in albino mice
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20151210Keywords:
Nimodipine, Methylphenidate, Psychosis, Haloperidol, Stereotypy, CatalepsyAbstract
Background: Schizophrenia is a functional psychotic disorder currently treated by typical and atypical antipsychotic drugs. A large group of patients remain resistant to therapy. Nimodipine has been found effective for treating resistant bipolar mood disorder which is linked genetically with schizophrenia and has a high overlap of neurotransmitters in the etiopathology. Previous studies to evaluate nimodipine’s antipsychotic activity have shown inconsistent results. Methylphenidate, a CNS stimulant like amphetamine, has been shown to induce stereotypy in animals and can be proposed as an alternative model for psychosis.
Methods: Methylphenidate 5 mg/kg was given intraperitoneally to induce psychosis in swiss albino mice (n=6). Nimodipine was given alone in doses of 2.5 and 5 mg/kg by i.p route and in combination with haloperidol 0.1 mg/kg and effects were compared with haloperidol 0.2mg/kg. Activity of nimodipine was also assessed on the haloperidol induced catalepsy test. Statistical analysis was done with ANOVA followed by Bonferroni’s test using SPSS v. 20.0.
Results: Methylphenidate successfully induced characteristic stereotypy behaviour in mice similar to amphetamine. Both nimodipine 5 mg/kg and haloperidol 0.2 mg/kg showed significant reduction in stereotypy behaviour with no statistical difference between the two; result with nimodipine were only slightly inferior to haloperidol. Nimodipine 5 mg/kg with haloperidol 0.1 mg/kg showed significantly better activity than haloperidol in standard dose of 0.2 mg/kg. Nimodipine did not show significant activity on the haloperidol induced catalepsy test.
Conclusions: Methylphenidate has potential to be used as an alternative model for inducing psychosis in animals and nimodipine shows promising results for use as adjuvant antipsychotic drug.
Metrics
References
Baldessarani RJ, Tarzai FI. Drug therapy of psychosis and mania. In: Brunton L, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill. 2006:461-80.
Schizophrenia. In: Sadock BJ, Sadock VA, eds. Synopsis of psychiatry: Behavioral Sciences/clinical Psychiatry.10th ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2007:410-520.
DeBattista C. Antipsychotic agents and lithium. In: Katzung BG, Trevor AJ, eds. Basic & clinical pharmacology.13th ed. New Delhi, India: Mc Graw Hill Education (India) private limited. 2015:490-509.
Solanki RK, Singh P, Munshi D. Current perspectives in the treatment of resistant schizophrenia. Indian J Psychiatry. 2009;51(4):254-60.
Möller HJ. Bipolar disorder and schizophrenia: distinct illnesses or a continuum? J Clin Psychiatry. 2003;64(6):23-7.
Bekker A, Haile M, Li YS, Galoyan S, Garcia E, Quartermain D, et al. Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice. Anesth Analg. 2009;109(6):1943-8.
Goodnick PJ. The use of nimodipine in the treatment of mood disorders. Bipolar Disord. 2000;2(3):165-73.
Kaygisiz B, Ozdemir M, Baydemir C. Modulation of the antipsychotic Effect of Ziprasidone with Nimodipine. Bulletin of Clinical Psychopharmacology. 2011;21(3):186-92.
Khanzode SD, Belorkar NR, Gosavi DD. Effect of pretreatment of nimodipine and nitrendipine on some dopaminergically mediated behaviours in rats. Indian J Pharmacol. 2000;32(3):235-8.
Inhibition of amphetamine stereotypy in rats. Chapter E.5.3.2. In: Vogel HG, ed. Drug Discovery and Evaluation. Pharmacological assays. 2nd ed. Heidelberg, Germany: Springer. 2002:535-37.
Randrup A, Munkavad I. Pharmacology and physiology of stereotyped behaviour. Psych J Research. 1974;11:1-10.
Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill. 2011:299.
Kuczenski R, Segal DS. Effects of Methyiphenidate on Extracellular Dopamine, Serotonin, and Norepinephrine: Comparison with Amphetamine. J. Neurochem. 1997;68(5):2032-7.
Morton WA, Stockton GG. Methylphenidate Abuse and Psychiatric Side Effects. Prim Care Companion J Clin Psychiatry 2000;2(5):159–64.
Balcioglu A, Ren JQ, McCarthy D, Spencer TJ, Biederman J, Bhide PG. Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice. Neuropharmacology. 2009;57(7-8):687-93.
Nishchal BS, Rai S, Prabhu MN, Ullal SD, Rajeswari S, Gopalakrishna HN. Effect of Tribulus terrestris on haloperidol-induced catalepsy in mice. Indian J Pharm Sci. 2014;76(6):564-67.
Catalepsy in rodents. Chapter E. 5.2.4. Vogel HG, ed. In: Drug discovery and evaluation. Pharmacological Assays. 2nd ed. Heidelberg, Germany: Springer. 2002:531.
Nair V, Arjuman A, Dorababu P, Gopalakrishna HN, Rao UC, Mohan L. Effect of NR-ANX-C (a polyherbal formulation) on haloperidol induced catalepsy in albino mice. Indian J Med Res. 2007;126(5):480-84.
Browne RG, Segal DS. Metabolic and experiential factors in the behavioural response to repeated amphetamine. Pharmacol Biochem Behav. 1977;6(5):545-52.
Segal DS, Kuczenski R. Behavioral pharmacology of amphetamine, in Amphetamine and Its Analogs. Cho AK, Segal DS, eds. In: Psychopharmacology, Toxicology and Abuse. 1st ed. San Diego, CA: Academic Press. 1994:115-50.
Neill DB, Grant LD, Grossman SP. Selective potentiation oflocomotor effects of amphetamine by midbrain raphe lesions. Physiol Behav. 1972;9(4):655-57.
Tilley MR, Gu HH. The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008;327(2):554-60.
Chakrabarti A, Saini HK, Garg SK. Dose-finding study with nimodipine: a selective central nervous system calcium channel blocker on aminophylline induced seizure models in rats. Brain Res Bull. 1998;45(5):495-9.
Meyer JM. Pharmacotherapy of psychosis and mania. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill. 2011:417-9.
Molinoff PB. Neurotransmission and the central nervpus system. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill. 2011:367-70.
Crespi D, Mennini T, Gobbi M. Carrier dependent and Ca++dependent 5-HT and DA release induced by amphetamine, 3,4 methelendioxmethyl amphetamine, p-chloramphetamine and fenfluramine. Br J Pharmacol. 1997;121(8):1735-43.
Pileblad E, Carlsson A. The Ca2+-antagonist nimodipine decreases and Ca2+-agonist Bay-K-8644 increases catacholamine synthesis in mouse brain. Neuropharmacol. 1987;26(1):101-5.
Czyrak A, Mogilnicka E, Siwanowicz J, Maj J. Some behavioural effects of repeated administration of calcium channel antagonists. Pharmacol Biochem Behav. 1990;35(3):557-60.
Biala G, Weglinska B. Calcium channel antagonists attenuate crosssensitization to the rewarding and/or locomotor effects of nicotine, morphine and MK-801. J Pharm Pharmacol. 2004;56(8):1021-8.
Yarlagadda A, Clayton AH. Role of Cholinergic System and Calcium Synchronization in Schizophrenia. Psychiatry (Edgmont). 2009;6(4):37-41.
Worthley LI, Holt AW. Acute haemorrhagic stroke. Crit Care Resusc. 2002;2(3):209-19.
Sarfati Y, Spadone C, Vanelle JM, Lôo H. Calcium antagonists and lithium in preventive treatment of manic-depressive disorder. Encephale.1996;22(2):149-53.
Essali A, Deirawan H, Soares-Weiser K, Adams CE. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;9(11):CD000206.
Downloads
Published
How to Cite
Issue
Section
